Dehydrated Human Umbilical Cord Allograft in the Management of Diabetic Foot Ulcers

Inclusion criteria

1\. Subject has a known history of Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA). 2\. Index ulcer characteristics: a. Ulcer present for ≥ 30 days prior to randomization (Day 0) b. Index ulcer is located below the ankle c. Index ulcer area after debridement is ≥ 1 cm² and ≤ 15 cm² at the randomization visit 3. Subject has completed 14-day run-in period with ≤ 30% wound area reduction post-debridement. 4\. Subject has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days: * Dorsum transcutaneous oxygen test (TcPO2) with results ≥ 30 mmHg, OR * ABIs with results of ≥ 0.7 and ≤ 1.2, OR * Doppler arterial waveforms, which are triphasic or biphasic at the ankle of the affected foot 5. Age ≥ 18 6. The subject is willing and able to provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study 1. Index Ulcer Assessment: 1. Penetrates down totendon, or bone 2. Presence of another diabetic foot ulcer within 3 cm of the index ulcer 3. Index ulcer determined to be due to active Charcot deformity or major structural abnormalities of the foot 4. Exhibits clinical signs and symptoms of infection 5. Known or suspected local skin malignancy to the index diabetic ulcer 6. Wound duration \> one year without intermittent closure 2. Prior therapies - Subjects receiving treatment with any of the following will not be eligible for enrollment: 1. In the last 7 days - Negative pressure wound therapy (wound vac or SNaP®) of the index ulcer 2. In the last 7 days - Hyperbaric oxygen (HBO) therapy 3. In the last 10 days - Chemical debridement, Dakin's solution, medical honey therapy 4. In the last 30 days - Treatment with cytotoxic chemotherapy, application of topical steroids to the ulcer surface, or use of ≥ 14 days of immune-suppressants (including systemic corticosteroids); or, subject is anticipated to require such medications during the course of the study 5. In the last 30 days - study ulcer treatment with any biological skin substitutes, including EpiCord, biomedical or topical growth factors, tissue engineered materials (e.g. Apligraf® or Dermagraft®), or other scaffold materials (e.g. OASIS® Wound Matrix, MatriStem® Wound Matrix, Grafix, etc.) 6. In the last 30 days - Subject has been on any investigational drug(s) or therapeutic device(s) 7. In the last 6 months - Amputation or revascularization (surgical or stenting) to the affected leg or foot 3. Subject criteria that will make subject ineligible for enrollment: 1. Known osteomyelitis or active cellulitis at wound site 2. Hemoglobin A1C \>12 in the last 60 days prior to randomization 3. History of Immune system disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired Immunodeficiency Syndrome (AIDS) or HIV 4. Allergy or known sensitivity to Aminoglycosides such as gentamicin sulfate and/or streptomycin sulfate 5. Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol in the judgment of the Investigator 6. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence) 7. Known history of poor compliance with medical treatments 8. Subjects currently enrolled in this study. Concurrent enrollment in the study is prohibited 9. Subjects currently receiving radiation therapy or chemotherapy 10. Patients currently on dialysis or planning to start dialysis